Drug Type Stem cell therapy |
Synonyms ORCA-Q, OrcaGraft, OrcaQ |
Target- |
Action- |
Mechanism Immunologic cytotoxicity, T lymphocyte replacements |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Acute Lymphoblastic Leukemia | Phase 2 | United States | 16 Aug 2022 | |
| Acute Myeloid Leukemia | Phase 2 | United States | 16 Aug 2022 | |
| Blast Phase Chronic Granulocytic Leukemia | Phase 2 | United States | 16 Aug 2022 | |
| Chronic phase chronic myeloid leukemia | Phase 2 | United States | 16 Aug 2022 | |
| High Risk Myelodysplastic Syndrome | Phase 2 | United States | 16 Aug 2022 | |
| Mixed phenotype acute leukemia | Phase 2 | United States | 16 Aug 2022 | |
| Refractory Acute Undifferentiated Leukemia | Phase 2 | United States | 16 Aug 2022 | |
| Multiple Sclerosis, Primary Progressive | Phase 1 | - | 01 Mar 2025 | |
| Multiple Sclerosis, Secondary Progressive | Phase 1 | - | 01 Mar 2025 | |
| Renal transplant rejection | Phase 1 | United States | - |
NCT03802695 (ASH2024) Manual | Phase 1 | 14 | eihhxdgzpc(tetzzbcash) = iedyniccgj pdobgoymuc (ehabgaibja ) View more | Positive | 07 Dec 2024 | ||
NCT03802695 (ASH2023) Manual | Phase 1 | 33 | dwqiyqgzbv(yxvkoyhzrc) = fbqapxcxue kwfmzhjpwp (xacwnlcjqv ) View more | Positive | 11 Dec 2023 | ||
Not Applicable | - | jcvjfukgrb(svhrejvmlw) = gxhzxsqepi ggsrvzacjl (nkymnunhpr ) View more | - | 01 Sep 2023 | |||
Phase 1 | 21 | Orca-Q cell therapy | zruuhxnyzs(ildoenxzuq) = tixqrkninf lknltbsctw (niyhiyqoex ) View more | Positive | 01 Feb 2023 |





